Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

<p>Abstract</p> <p>Objective</p> <p>To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada.</p> <p>Methods</p> <p>A Markov model was con...

Full description

Bibliographic Details
Main Authors: Assasi Nazila, Blackhouse Gord, Xie Feng, Gaebel Kathryn, Robertson Diana, Goeree Ron
Format: Article
Language:English
Published: BMC 2009-12-01
Series:Cost Effectiveness and Resource Allocation
Online Access:http://www.resource-allocation.com/content/7/1/20

Internet

http://www.resource-allocation.com/content/7/1/20

Similar Items